Novo Nordisk’s GLP-1 Pill Secures FDA Approval
Shares in Novo Nordisk surged over 7% Tuesday, after the Wegovy maker secured approval of its GLP-1 pill — a world first.
The U.S. Food and Drug Administration’s approval of Novo Nordisk’s GLP-1 pill gives the Danish pharmaceutical giant a head start over U.S. rival Eli Lilly.
Market Reaction and Competition
The pill’s starting dose of 1.5 milligrams will be available in pharmacies and via select telehealth providers with savings offers for $149 per month in early January, the firm said.
Cash-paying patients can access it for the same price via President Donald Trump’s direct-to-consumer website, TrumpRx, according to the deal Novo Nordisk struck with his administration last month.
Expert Analysis
Rajesh Kumar, who heads up European life Sciences and healthcare equity research at HSBC, told CNBC’s “Squawk Box Europe” on Tuesday that Novo’s clinical data looks “fantastic.”
It has food and water restrictions, which may make it harder for GPs to prescribe but its tolerability and efficacy are better than Eli Lilly’s pill, Kumar said.
Market Share and Future Outlook
Novo actually might have an edge, and it will entirely depend on how they execute, Kumar added.
Lilly also reported positive findings from a maintenance trial where patients switched directly from taking the company’s injection Zepbound and Novo Nordisk’s rival shot Wegovy.
Source: Link
